rAAV-CaMKlla
Recombinant adeno-associated viruses (rAAVs) are widely used as vectors for gene delivery in neuroscience and related fields. The CaMKIIα promoter, derived from the gene encoding calcium/calmodulin-dependent protein kinase II alpha, is a neuron-specific promoter commonly used for targeting excitatory neurons.
Features of rAAV-CaMKIIα
- Neuron-Specific Expression:
- The CaMKIIα promoter ensures gene expression is restricted primarily to excitatory neurons in the central nervous system (CNS).
- Minimal expression in glial cells or inhibitory neurons, improving targeting specificity.
- Activity-Dependent Targeting:
- CaMKIIα expression is regulated by neuronal activity, making it suitable for studies on active neural circuits.
- Efficiency:
- Supports high-level, long-term expression of transgenes in neurons.
Applications of rAAV-CaMKIIα
- Neuroscience Research:
- Optogenetics: Delivery of channelrhodopsins or halorhodopsins to modulate excitatory neural activity.
- Calcium Imaging: Expression of fluorescent calcium indicators (e.g., GCaMP) to monitor neuronal activity.
- Behavioral Studies: Manipulation of specific neural circuits to study their roles in learning, memory, and behavior.
- Gene Therapy:
- Experimental treatment of CNS disorders where excitatory neurons are implicated (e.g., epilepsy, stroke recovery).
- Circuit Mapping:
- Tracing synaptic connections using retrograde or anterograde tracers under the CaMKIIα promoter.
- Identifying functional contributions of excitatory neurons in specific brain regions.
- Functional Genomics:
- Overexpression or silencing of genes specifically in excitatory neurons to study gene function.
- Targeted CRISPR/Cas9 genome editing in excitatory neurons.
rAAV-CaMKIIα is a precise and efficient tool for studying excitatory neuron function, mapping neural circuits, and developing targeted therapeutic strategies for CNS disorders. It has become a cornerstone in the field of neuroscience.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|